Correction to: miRNA Profile and Bioinformatic Analysis for Diagnosis in Patients with Stage IIIA Colon Cancer

e15076 Background: With the advent of colon cancer screening, patients with early stage colon cancer will be more common in our clinics. The evidence supporting the absolute benefit of chemotherapy in resected Stage II and (to a lesser extent) Stage IIIA disease is poor. Not all patients benefit from chemotherapy and toxicity is a problem. There is a need for validated biomarkers to assess individual patient recurrence risk and discriminate absolute treatment benefit. Several studies have validated the role of the OncotypeDX testing in Stage II/IIIA disease. Our objective is to characterize whether this test impacted oncologists’ decisions in treating patients with Stage II/IIIA in the adjuvant setting. Methods: :The Onco typeDX assay is a multi-gene reverse-transcriptase-polymerase-chain-reaction test that analyses the expression of 12 genes involved in key biologic pathways in colon cancer. Stage II and Stage IIIA colon cancers were studied in affiliated hospitals of our region in southwest Ireland. All data collected is prospective and each colon cancer was assigned a recurrence risk score. Oncologists were blinded to this score and the decision to prescribe adjuvant chemotherapy was recorded. After un-blinding the score, a second decision was recorded and comparisons made. Results: :From August 2015 to September 2016, 70 patients have been recruited with M: F of 2:1. Median age at diagnosis was 65 years. Most patients (80%) had stage II disease, 11 of whom had mismatch repair loss on IHC. OncotypeDX testing has been carried out and reported for 59 patients (85%), MMR intact. Recurrence scores: < 30 in 46 patients (77.9%), 30-40 in 10 patients, and > 40 in 3 patients. The treatment plan was altered in 16 patients (27%), of whom 12 patients (20%) received none or less intense chemotherapy. Conclusions: We have shown that the decision to prescribe adjuvant chemotherapy was changed in 27% of patients. This test has helped to define patients with low scores, where chemotherapy-related toxicity is a concern especially in older patients. Absolute benefit of adjuvant chemotherapy versus the risk of toxicity should be discussed. . Hospital managers may be interested in cost savings due to a reduction in chemotherapy use.

Download Full-text

Poor survival in stage IIB/C (T4N0) compared to stage IIIA (T1-2 N1, T1N2a) colon cancer persists even after adjusting for adequate lymph nodes retrieved and receipt of adjuvant chemotherapy

BMC Cancer ◽

10.1186/s12885-016-2446-3 ◽

2016 ◽

Vol 16 (1) ◽

Cited By ~ 12

Author(s):

Quyen D. Chu ◽

Meijiao Zhou ◽

Kaelen L. Medeiros ◽

Prakash Peddi ◽

Mindie Kavanaugh ◽

...

Keyword(s):

Colon Cancer ◽

Adjuvant Chemotherapy ◽

Lymph Nodes ◽

Poor Survival ◽

Stage Iiia

Download Full-text

Molecular pathway analysis indicates a distinct metabolic and immune phenotype in women with right-sided colon cancer

10.1101/659151 ◽

2019 ◽

Author(s):

Yazhi Sun ◽

Varvara Mironova ◽

Ying Chen ◽

Elliott P.F. Lundh ◽

Qian Zhang ◽

...

Keyword(s):

Gene Expression ◽

Colon Cancer ◽

Transverse Colon ◽

Clinical Importance ◽

Bioinformatic Analysis ◽

The United States ◽

Anatomical Location ◽

Nutrient Metabolism ◽

Immune Phenotype ◽

Tumor Tissues

AbstractColon cancer is the third most commonly diagnosed cancer in the United States. Recent reports have shown that the location of the primary tumor is of clinical importance. Patients with right-sided cancers (RCCs) (tumors arising between the cecum and proximal transverse colon) have poorer clinical outcomes than those with left-sided colon cancers (LCCs) (tumors arising between the distal transverse colon and sigmoid colon, excluding the rectum). Interestingly, women have a lower incidence of colon cancer than men do. However, women have a higher propensity for RCC than men. Identification of gene expression differences between RCC and LCC is considered a potential means of prognostication. Furthermore, studying colon cancer sidedness could reveal important predictive markers for response to various treatments. This study provides a comprehensive bioinformatic analysis of various genes and molecular pathways that correlated with sex and anatomical location of colon cancer using four publicly available annotated datasets housed in the National Center for Biotechnology Information’s Gene Expression Omnibus (GEO). We identified differentially expressed genes in tumor tissues from women with RCC, which showed attenuated energy and nutrient metabolism when compared to women with LCC. Specifically, we showed that the downregulation of 5’ AMP-activated protein kinase alpha subunit (AMPKα) and downregulated anti-tumor immune response in women with RCC. This difference was not seen when comparing tumor tissues from men with RCC to men with LCC. Therefore, women with RCC may have a specific metabolic and immune phenotype which accounts for differences in prognosis and treatment response.

Download Full-text

Bioinformatic analysis of CCA-1.1, a novel curcumin analog, uncovers furthermost noticeable target genes in colon cancer

Gene Reports ◽

10.1016/j.genrep.2020.100917 ◽

2020 ◽

Vol 21 ◽

pp. 100917

Author(s):

Febri Wulandari ◽

Muthi' Ikawati ◽

Edy Meiyanto ◽

Mitsunori Kirihata ◽

Adam Hermawan

Keyword(s):

Colon Cancer ◽

Target Genes ◽

Bioinformatic Analysis ◽

Curcumin Analog

Download Full-text

Re-Evaluation of the Survival Paradox Between Stage IIB/IIC and Stage IIIA Colon Cancer

Frontiers in Oncology ◽

10.3389/fonc.2020.595107 ◽

2020 ◽

Vol 10 ◽

Author(s):

Hongbo Li ◽

Guangshun Fu ◽

Wei Wei ◽

Yong Huang ◽

Zhenguang Wang ◽

...

Keyword(s):

Colon Cancer ◽

Stage Iiia

Download Full-text

lncRNA-PCAT1 rs2632159 polymorphism could be a biomarker for colorectal cancer susceptibility

Bioscience Reports ◽

10.1042/bsr20190708 ◽

2019 ◽

Vol 39 (7) ◽

Cited By ~ 5

Author(s):

Ming-li Yang ◽

Zhe Huang ◽

Li-na Wu ◽

Rong Wu ◽

Han-xi Ding ◽

...

Keyword(s):

Colorectal Cancer ◽

Rectal Cancer ◽

Colon Cancer ◽

Cancer Risk ◽

Cancer Susceptibility ◽

Bioinformatic Analysis ◽

Recessive Model ◽

Eqtl Analysis ◽

Nucleotide Polymorphisms ◽

Colon Cancer Risk

AbstractBackground: Single-nucleotide polymorphisms (SNPs) in lncRNAs could be biomarkers for susceptibility to colorectal cancer (CRC), but the association of PCAT1 polymorphisms and CRC susceptibility is yet to be studied. Methods: Five tagSNPs covering the PCAT1 gene were detected through Kompetitive Allele-Specific PCR among 436 CRC patients and 510 controls. An expression quantitative trait locus (eQTL) bioinformatic analysis was then performed. Results: In the present study, PCAT1 rs2632159 polymorphism increased CRC risk by 1.37-fold and 2.19-fold in the dominant and recessive models, respectively (P=0.040 and 0.041). When the CRC cases were divided into colon cancer and rectal cancer, we found that this polymorphism affected colon cancer risk under the dominant model (P=0.022, OR = 1.51) and affected rectal cancer susceptibility under the recessive model (P=0.009, OR = 3.03). A more pronounced effect was observed in the male subgroup in that PCAT1 rs2632159 SNP increased rectal cancer risk by 3.97-fold (P=0.017). When PCAT1 rs2632159 was present, epistatic effects were observed with rs1902432 and rs785005 (P=0.011 and 0.008, respectively). eQTL analysis showed that rs2632159 could influence binding with the transcription factors EBF, LUN-1, and TCF12. Conclusion:PCAT1 rs2632159 SNP could be a biomarker for CRC risk. And the rs1902432 SNP might only have potential to be a biomarker for colon cancer risk.

Download Full-text